Kita-kyushu lung cancer antigen 1 (76-84)

Kita-kyushu lung cancer antigen 1 (76-84) is a synthetic peptide fragment derived from the larger Kita-kyushu lung cancer antigen 1 protein, a tumor-associated antigen identified in certain cancer cell lines. As a defined nonapeptide, it represents a minimal epitope sequence recognized by the immune system, making it highly relevant for studies in tumor immunology and antigen-specific immune responses. Its well-characterized amino acid sequence and reproducible synthesis enable researchers to explore peptide-MHC interactions, T cell recognition, and other fundamental aspects of cellular immunity. The availability of this peptide in research-grade form supports advanced investigations into cancer biology and immunotherapeutic strategies, as well as the development of analytical techniques for antigen detection and characterization.

Epitope mapping: The 76-84 fragment of Kita-kyushu lung cancer antigen 1 serves as a valuable tool for epitope mapping studies, enabling researchers to define the specific regions of the parent protein that are recognized by cytotoxic T lymphocytes. By employing this peptide in functional assays, investigators can dissect T cell receptor specificity and identify the immunodominant determinants that drive anti-tumor immune responses. Such mapping is essential for understanding immune surveillance mechanisms and for the rational design of peptide-based immunotherapeutics.

T cell activation assays: As a synthetic peptide corresponding to a known tumor-associated epitope, this compound is widely utilized in T cell activation assays. It can be loaded onto antigen-presenting cells or coated onto assay plates to stimulate antigen-specific T cells in vitro. Measuring the resulting cytokine production, proliferation, or cytotoxic activity provides insights into T cell responsiveness, specificity, and functional avidity, supporting both basic and translational research in cancer immunology.

Peptide-MHC binding studies: The defined sequence of this nonapeptide allows for detailed investigation of peptide-major histocompatibility complex (MHC) interactions. Researchers can employ it to assess binding affinity and stability with various MHC class I molecules, facilitating the characterization of antigen presentation pathways. These studies are instrumental in elucidating how tumor antigens are processed and displayed to the immune system, informing the development of targeted immunotherapies and diagnostic assays.

Immunogenicity assessment: The peptide's role as a minimal antigenic determinant makes it suitable for evaluating immunogenicity in preclinical models. By incorporating the peptide into immunization protocols or ex vivo assays, scientists can quantify and compare immune responses elicited by different antigenic sequences. Such assessments are critical for optimizing peptide vaccine candidates and for understanding the parameters that govern effective immune recognition of tumor antigens.

Analytical reference standard: In addition to its immunological applications, this synthetic peptide serves as a reliable analytical reference in mass spectrometry and chromatographic techniques. Its defined structure and purity facilitate the calibration of analytical instruments and the validation of peptide detection workflows. Employing this peptide as a standard enhances the accuracy of quantitative analyses in proteomics studies, particularly those focused on tumor antigen profiling and biomarker discovery.

1. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

2. Exosomes-mediated Transfer of miR-125a/b in Cell-to-cell Communication: A Novel Mechanism of Genetic Exchange in the Intestinal Microenvironment

3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

4. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

5. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction